Breed: Labrador Retriever
Gender: MALE, NEUTERED
Splenic mass, splenectomy.
Low magnification view of the lesion (as submitted), demonstrating proliferative vascular mass effacing normal splenic parenchyma.
Higher magnification view of the lesion (40X), demonstrating proliferative vascular channels lined by plump endothelial cells.Click here for the IDEXX Pathology Report on this case.
Two incisional biopsies of the spleen are submitted, from these samples 5 sections are evaluated. Throughout the specimen there is a poorly demarcated, unencapsulated neoplasm comprised of numerous, torturous small blood vessels and other areas where the neoplastic cells form dense sheets of spindloid cells. Endothelial cells lining these vessels are supported by a dense basement membrane. These cells have abundant eosinophilic cytoplasm and an oval, hyperchromatic nucleus that often protrudes into the vascular lumen. Mitotic figures average 9 per 10 high power fields. There is blood, hemosiderin and hematoidin pigment throughout the mass. Neoplastic cells extend to the margins.
Spleen: Splenic hemangiosarcoma
9 (9 mitotic figures per 10 high power fields)
Extends to surgical margins.
Hemangiosarcoma (HSA) is a malignant neoplasm of vascular endothelial origin. It represents about 5% of all noncutaneous primary malignant neoplasms and 12-21% of all mesenchymal neoplasms in the dog. HSA accounts for 45-51% of splenic malignancies. HSA are seen mostly in middle-aged to older animals, and German Shepherds, Golden Retrievers, and Labrador Retrievers are overrepresented. There may also be a slight male predisposition.
The mean survival in a large group of dogs with splenic hemangiosarcoma of this type was two months with 93-100% mortality twelve months postoperatively. Anticipated complications include metastasis to the liver, continued abdominal bleeding, seeding of tumor cells to adjacent visceral or mesenteric surfaces, coagulation anomalies (DIC), and abnormal erythrocyte morphology.